Insulin resistance is the metabolic condition underlying prediabetes, type 2 diabetes, PCOS, and much of what gets labeled "stubborn weight gain" — yet it's rarely diagnosed directly. Most patients are told their glucose is normal and never learn that their fasting insulin has been climbing for years. This guide covers how a clinician actually diagnoses insulin resistance, which labs matter, and why fasting glucose alone misses it.
- Insulin resistance is diagnosed with fasting insulin, HbA1c, and HOMA-IR — not fasting glucose alone.
- It can be present for 5-10 years before fasting glucose rises above normal.
- Fasting insulin above 10 uIU/mL indicates insulin resistance even with normal glucose; above 15 uIU/mL is significant.
- HOMA-IR above 2.9 indicates significant insulin resistance; above 5.0 indicates severe insulin resistance.
- The condition is reversible with structured lifestyle change, and GLP-1 medication improves insulin sensitivity directly when lifestyle alone isn't enough.
- Waist circumference and the triglyceride-to-HDL ratio add supporting evidence beyond standard glucose testing.
TL;DR
Insulin resistance means your cells respond poorly to insulin's signal to absorb glucose, so the pancreas compensates by producing more insulin — driving fat storage, inflammation, and eventually prediabetes. Verdict: insulin resistance is diagnosed with fasting insulin (not just glucose), HbA1c, and sometimes a calculated HOMA-IR — and it can be present for 5-10 years before fasting glucose rises above normal. A clinician who checks only fasting glucose misses the window where intervention is most effective. The condition is reversible with structured lifestyle change, and when lifestyle alone isn't enough, GLP-1 medication improves insulin sensitivity directly.
Why This Matters
Insulin resistance is not a binary diagnosis — it's a spectrum that progresses silently. The pancreas can compensate for years by producing more insulin, keeping glucose in the normal range while insulin levels climb higher and higher. During this compensatory phase, the patient has normal glucose but elevated insulin, and they're told everything is fine. By the time glucose rises (prediabetes: HbA1c 5.7-6.4%, or diabetes: HbA1c 6.5%+), insulin resistance is already advanced and the pancreas is beginning to fail.
This matters because insulin resistance is the driver of several conditions that are treated as separate problems: visceral fat accumulation, PCOS (elevated insulin stimulates ovarian androgen production), non-alcoholic fatty liver disease (insulin resistance drives hepatic fat storage), hypertension (insulin resistance impairs nitric oxide-mediated vasodilation), and the metabolic syndrome cluster. Diagnosing and treating insulin resistance addresses the root cause, not each downstream condition independently.
What You'll Need
- Fasting insulin level (drawn after 10-12 hour fast) — this is the test most often skipped
- Fasting glucose or HbA1c
- A comprehensive metabolic panel (liver markers, kidney function)
- A lipid panel (triglycerides and HDL are markers of insulin resistance)
- A waist circumference measurement
- A clinician who interprets fasting insulin in context, not just glucose
The Steps
1. Check fasting insulin, not just fasting glucose
Fasting glucose is the last marker to change in insulin resistance. The pancreas compensates by producing more insulin to keep glucose normal — so glucose stays in range while insulin climbs. A fasting insulin above 10 uIU/mL indicates insulin resistance even when glucose is normal. A fasting insulin above 15 uIU/mL indicates significant insulin resistance. This is the single most important lab for early diagnosis, and it's the one most clinicians don't order. Common mistake: checking fasting glucose, seeing it's normal, and concluding there's no insulin resistance — the compensatory phase is exactly when glucose is normal but insulin is high.
2. Calculate HOMA-IR for a quantified measure
HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) is calculated from fasting glucose and fasting insulin: (fasting insulin x fasting glucose) / 405. A HOMA-IR below 1.0 indicates good insulin sensitivity. 1.0-2.9 indicates mild insulin resistance. Above 2.9 indicates significant insulin resistance. Above 5.0 indicates severe insulin resistance. This calculation transforms two lab values into a single number that tracks insulin resistance over time and responds to intervention. Common mistake: not calculating HOMA-IR even when both insulin and glucose were drawn — the raw values are harder to interpret than the calculated index.
3. Check HbA1c for the 3-month glucose picture
HbA1c reflects average blood glucose over the previous 2-3 months. Below 5.7% is normal. 5.7-6.4% is prediabetes. 6.5% and above is diabetes. HbA1c is useful because it captures post-meal glucose spikes that fasting glucose misses — a patient can have a normal fasting glucose of 92 mg/dL but an HbA1c of 5.9% because their post-meal glucose is spiking to 180 mg/dL. Common mistake: relying on fasting glucose alone and missing postprandial glucose elevation that HbA1c captures.
4. Evaluate the triglyceride-to-HDL ratio
The triglyceride-to-HDL ratio is one of the strongest lipid-based markers of insulin resistance. A ratio above 3.0 (using mg/dL units) strongly suggests insulin resistance. A ratio above 2.0 is borderline. This ratio is available on any standard lipid panel and costs nothing additional. Triglycerides rise in insulin resistance because insulin stimulates hepatic triglyceride production, and HDL drops because insulin resistance reduces HDL clearance. Common mistake: looking at triglycerides and HDL individually without calculating the ratio, which is more predictive than either value alone.
5. Check liver markers for fatty liver
ALT above 40 IU/L (men) or 32 IU/L (women) suggests non-alcoholic fatty liver disease (NAFLD), which is both a consequence and a driver of insulin resistance. Elevated ALT with elevated triglycerides and insulin resistance is a pattern that requires intervention — not just monitoring. An abdominal ultrasound or FibroScan confirms hepatic fat. NAFLD is reversible with the same interventions that improve insulin sensitivity. Common mistake: dismissing ALT of 45 as a minor elevation when it's actually early fatty liver disease.
6. Measure waist circumference
Waist circumference above 40 inches (men) or 35 inches (women) indicates excess visceral fat, which is both a cause and consequence of insulin resistance. Waist circumference is more predictive of insulin resistance than BMI because it measures the fat depot most metabolically active in driving insulin resistance. A patient with a normal BMI but waist circumference above 40 inches can still have significant insulin resistance. Common mistake: relying on BMI and never measuring waist circumference, missing the "thin outside, fat inside" phenotype.
7. Consider an oral glucose tolerance test (OGTT) for borderline cases
When fasting labs are borderline (insulin 8-12 uIU/mL, HbA1c 5.4-5.7%), a 2-hour oral glucose tolerance test with insulin measurements can reveal insulin resistance that fasting labs miss. The test measures glucose and insulin at baseline, 30 minutes, 1 hour, and 2 hours after a 75g glucose load. An insulin peak above 100 uIU/mL at 30-60 minutes or failure to return to near-baseline by 2 hours indicates insulin resistance. This is more sensitive than fasting labs but requires more time and is typically reserved for borderline cases. Common mistake: skipping the OGTT when fasting labs are borderline, when the OGTT would reveal early insulin resistance.
Insulin Resistance Lab Thresholds at a Glance
Values drawn from the diagnostic steps above
| Marker | Threshold | What it indicates |
|---|---|---|
| Fasting insulin | Above 10 uIU/mL | Insulin resistance even with normal glucose |
| Fasting insulin | Above 15 uIU/mL | Significant insulin resistance |
| HOMA-IR | 1.0-2.9 | Mild insulin resistance |
| HOMA-IR | Above 2.9 | Significant insulin resistance |
| HOMA-IR | Above 5.0 | Severe insulin resistance |
| HbA1c | 5.7-6.4% | Prediabetes |
| HbA1c | 6.5%+ | Diabetes |
| Triglyceride-to-HDL ratio | Above 3.0 (mg/dL) | Strongly suggests insulin resistance |
| ALT | Above 40 IU/L (men) / 32 IU/L (women) | Suggests NAFLD |
| Waist circumference | Above 40 inches (men) / 35 inches (women) | Excess visceral fat |
Troubleshooting Common Setbacks
Fasting insulin is high but glucose and HbA1c are normal. This is the compensatory phase of insulin resistance. The pancreas is producing extra insulin to keep glucose normal. This is the ideal time to intervene — the condition is most reversible here.
Fasting insulin improved but weight isn't moving. Insulin sensitivity can improve before fat loss accelerates — the metabolic environment has to shift before fat mobilization increases. Continue the protocol and recheck at 3 months.
Started a GLP-1 medication and insulin levels dropped fast. GLP-1 medications improve insulin sensitivity directly, beyond their effect on weight loss. This is expected and beneficial — the medication is addressing the root cause.
Fasting insulin is normal but triglyceride-to-HDL ratio is high. Check for other causes of elevated triglycerides: alcohol intake, refined carbohydrate consumption, or genetic hypertriglyceridemia. Insulin resistance may still be present but compensated.
Fasting insulin is high but glucose and HbA1c are normal — this is the compensatory phase, when the pancreas is producing extra insulin to keep glucose normal. It's the ideal time to intervene, since the condition is most reversible here.
Tools and Resources
- A clinician who orders fasting insulin (not just glucose) and calculates HOMA-IR
- A medical weight loss program that evaluates insulin resistance as the root cause of weight gain
- A direct primary care membership that includes the full metabolic panel and ongoing monitoring
- A waist circumference tape measure for weekly tracking
What to Do Next
If your fasting insulin is above 10 uIU/mL or your triglyceride-to-HDL ratio is above 3.0, the next step is a structured metabolic protocol — not just another glucose check. GoodLife Health's medical weight loss program includes the full insulin resistance workup and a protocol designed to improve insulin sensitivity.
The most important number on your metabolic lab panel is not your glucose — it's your fasting insulin.
FAQ
How do doctors diagnose insulin resistance? A clinician diagnoses insulin resistance with fasting insulin (the most important and most-skipped test), fasting glucose, HbA1c, and the calculated HOMA-IR. The triglyceride-to-HDL ratio and waist circumference add supporting evidence.
What fasting insulin level indicates insulin resistance? Fasting insulin above 10 uIU/mL suggests insulin resistance, even when glucose is normal. Above 15 uIU/mL indicates significant insulin resistance. Below 5 uIU/mL is ideal.
Can you have insulin resistance with normal blood sugar? Yes — this is the compensatory phase. The pancreas produces extra insulin to keep glucose normal, so glucose stays in range while insulin climbs. This phase can last 5-10 years before glucose rises.
What is HOMA-IR? HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) is a calculated index: (fasting insulin x fasting glucose) / 405. Below 1.0 is good, 1.0-2.9 is mild resistance, above 2.9 is significant resistance.
Does insulin resistance cause weight gain? Yes — elevated insulin promotes fat storage and inhibits fat breakdown. Insulin resistance creates a metabolic environment where the body preferentially stores rather than burns fat, even in a calorie deficit.
Is insulin resistance reversible? Yes, especially in the compensatory phase (high insulin, normal glucose). Resistance training, protein-forward eating, sleep optimization, and weight loss can restore insulin sensitivity. GLP-1 medication improves insulin sensitivity directly when lifestyle changes plateau.
What's the best diet for insulin resistance? A diet that minimizes insulin spikes: adequate protein at every meal, high fiber (30+ grams daily), reduced refined carbohydrates, and controlled portion sizes. The specific macron
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/